Harvard Bioscience Seeks Shareholder Approval for Reverse Stock Split to Avoid Nasdaq Delisting
HBIO has more than doubled off its 52-week low of $0.281.
Summary
Harvard Bioscience, Inc. is seeking shareholder approval for a reverse stock split, with a ratio between 1-for-5 and 1-for-15, to regain compliance with Nasdaq's minimum $1.00 bid price requirement and avoid delisting.
Key Events · Corporate Governance and Compliance · HBIO
-
Reverse Stock Split Proposal
Shareholders will vote on an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio of 1-for-5 to 1-for-15.
-
Nasdaq Compliance Requirement
The primary purpose of the reverse stock split is to regain compliance with Nasdaq's minimum $1.00 bid price requirement by March 30, 2026, to avoid delisting.
-
Board Recommendation
The Board of Directors unanimously recommends voting 'FOR' the reverse stock split proposal.
-
Potential Risks
The company notes that a reverse split does not guarantee a sustained increase in share price or continued Nasdaq compliance, and could lead to further value loss or reduced liquidity.
Analysis · HBIO · Industrial Applications And Services
Harvard Bioscience, Inc. is facing a critical deadline to regain compliance with Nasdaq's minimum $1.00 bid price requirement by March 30, 2026, to avoid delisting. The proposed reverse stock split, with a flexible ratio between 1-for-5 and 1-for-15, is a necessary measure to increase the per-share price and maintain its listing. While this action aims to prevent delisting, which would severely impair the company's ability to raise capital and reduce liquidity, it does not address underlying business fundamentals. The company acknowledges that a reverse split carries risks, including the possibility that the share price may not increase proportionately or be sustained, potentially leading to further value loss.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HBIO was trading at $0.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $25.9M. The 52-week trading range was $0.28 to $1.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.